INTRODUCTION

Diabetes mellitus (DM) is a major health problem in the world. DM is a long-term condition of increased levels of glucose in the blood because the body cannot produce sufficient insulin or does not effectively use the insulin it produces. Insulin is an essential hormone in the body produced by the pancreas that converts glucose into energy. In addition, insulin also plays a role in fat and protein metabolism [1]. Prolonged insulin deficiency can cause damage to various organs of the body, especially the eyes, kidneys, nerves, heart, and blood vessels [2].

The prevalence of diabetes mellitus is continuously increasing worldwide. In 2019, there were 463 million (9.3%) people aged 20 to 79 y diagnosed with diabetes. It is estimated that the number of sufferers will continue to increase to reach 578 million (10.2%) in 2030 and reach 760 million (10.9%) in 2045. Especially in Indonesia with around 103 million people with diabetes, which is the largest in the world after China (114.4 million people), India (72.9 million people), the United States (30.2 million people), Brazil (12.5 million people), and Mexico (12 million people). It is estimated that the prevalence will increase to 1.67 million people in 2045 [1]. Based on this, it is necessary to do prevention or treatment to improve the health status of each individual.

Most people in carrying out maintenance and improvement of health and treatment of disease, still use traditional medicine or plants with medicinal properties. One of the traditional medicines used is Lawsonia inermis [3, 4]. Apart from being antidiabetic, pharmacologically, L. inermis has many activities, including analgesic, anti-inflammatory, antimalarial, antimicrobial, antifungal, antiviral, antiparasitic, anthelmintic, antifertility, tuberculostatic, hepatoprotective, antioxidant, anticancer, hypolipidemic, and immunomodulatory [5, 6]. The leaf part of the L. inermis plant is used traditionally, by boiling with water, and used as a medicine to relieve itching and ulcers due to increased blood sugar levels, and the leaves are also used as a healer for skin wounds [7]. This plant is reported to contain quinone compounds, phenylpropanoids, flavonoids, terpenoids, phenolics, fatty acids, steroids, tannins, gallic acid, mannotol, resins, fats, and mucilage [8-10]. Several studies also reported the chemical content of the leaves, namely 2 hydroxy 1,4 naphthoquinone 1,4 dihydroxy naphthalene, 1,4 naphthoquinone, 1,2 dihydroxy naphthoylnaphthalene and 2 hydroxy 1,4 glucosyloxynaphthalene [11].

A previous report showed that the percentage reduction in blood glucose level of hydroalcoholic extract of L. inermis leaves at a dose 400 mg/kg in rats was 39.08% on day 21 [12]. Research by Antika et al. [13] showed that the ethanolic extract of L. inermis leaves at doses of 200 mg/kg BW, 400 mg/kg BW and 600 mg/kg BW could reduce blood glucose levels in rats during 28 d of administration. In addition, the results of research by Zahara et al. [14] showed that administration of the ethyl acetate fraction at a dose of 600 mg/kg BW from L. inermis leaves significantly reduced blood sugar levels in rats. Based on the several studies that have been carried out, many benefits can be obtained from the plant, but scientific information related to the potential antidiabetic activity fractions of purified extract L. inermis leaves is not yet available and scientifically proven for its chemical content to treat as antidiabetic.

MATERIALS AND METHODS

Chemical and reagents

L. inermis leaves were collected from Lamonae Village, Wiwirano District, North Konawe Regency. The part used was the leaves.

ABSTRACT

Objective: This research was conducted to determine the potential antidiabetic activity fractions of purified extract Lawsonia inermis leaves in mice (Mus musculus) and identification of the compound.

Methods: The method included maceration, purification using ethanol and distilled water was followed by liquid-liquid extraction using ethyl acetate and magnesium sulfate as drying agents. Furthermore, the extract was analyzed using thin layer chromatography (TLC) for testing the purified extract. Fractionation using vacuum liquid chromatography, antidiabetic activity test of fractions at dose 100 mg/kgBW with alloxan induced and compound identification by Liquid Chromatography-Mass Spectrometry (LC-MS/MS) using HPLC connected to a Q-TOF spectrometer equipped with an ESI source, with Phenomenon column C8, and methanol with 0.3% formic acid as solvent.

Results: The results showed that from the purification step of L. inermis leaves by vacuum liquid chromatography method, 7 fractions were obtained, i.e. A-G fractions. While the antidiabetic activity of fractions shown by decreasing blood sugar level in mice on the 15th day were 64, 75, 73, 57, 45 and 67%, respectively. The identified compounds from each fraction were the ester groups namely 12-hydroxymethyl abietate, 9,12-octadecadienoic acid (Z,Z)-(2,2,4-dimethyl-1,3-dioxolan-4-yl)methyl ester, dehydrodromorronia glycone, and (E)-hexa decyl-ferulate; the steroid group namely stearic acid E; phenylpropanoid groups namely umbelliferone and bletilol C, and the alkaloid groups namely moupinamide and valine.

Conclusion: L. inermis leaves had activity in lowering blood sugar levels. LC-MS/MS analysis revealed the presence of ester groups, steroid groups, phenylpropanoid groups and alkaloid groups. The presence of these compounds mostly contribute to antidiabetic activity.

Keywords: L. inermis, Fractions, Anti-diabetic, Liquid chromatography-mass spectrometry
Determination was carried out in the laboratory of the School of Life Sciences and Technology, Bandung Institute of Technology, Indonesia. The materials used were distilled water, 96% ethanol, ethyl acetate, MgSO\(_4\), cerium sulfate, silica gel 60, 0.063-0.200 mm (E. Merck), Silica gel 60 GF 254 (E. Merck), TLC silica gel 60 GF 254, alloxan monohydrate (Novomix\(_\text{®}\)), Acarbose (pharmaceutical chemicals), mice (Swiss Webster strain), Sodium Carboxymethyl Cellulose (Na-CMC) (Pharmaceutical), n-hexane, acetone p.a., methanol p.a., chloroform p.a.

**Extraction**

The dry leaf powder \(L.\ inermis\) leaves which has been obtained was 3 kg. The sample was extracted by maceration method using 96% ethanol solvent until completely immersed for 3 x 24 h. This was carried out by the evaporation process and obtained 584.86 g of concentrated ethanol extract of \(L.\ inermis\) leaves. The yield of \(L.\ inermis\) leaves was obtained 19.49%.

**Purified extract**

Chlorophyll contained in the sample was removed by adding methanol: distilled water (1:1), stirring and allowed to stand for 1x24 h. The precipitate, which is chlorophyll was separated from the filtrate. The 1.3 L chlorophyll filtrate was partitioned with ethyl acetate (1:1). Ethyl acetate phase was then added with MgSO\(_4\) as a drying agent, and filtered. The ethyl acetate phase was concentrated with a Rotary Vacuum Evaporator so that 40 grams of ethyl acetate extract was obtained. Furthermore, the extract was analyzed using thin-layer chromatography (TLC) to determine the separation pattern of each fraction that was separated using n-hexane eluent: ethyl acetate (1:1) [15].

**Fractionation by vacuum liquid chromatography**

Fractionation begins with packing the column. The chromatographic column was packed dry in a vacuum in order to obtain the maximum packing density. Ethyl acetate extract of \(L.\ inermis\) leaves as much as 20 g was put into a vacuum liquid chromatography column that had been prepared with silica gel as a stationary phase and then eluted using a mixed eluent of n-hexane and ethyl acetate in a row with the ratio of eluent used was n-hexane: ethyl acetate: 82:4 times, (7:3) 4 times, (5:5) 4 times, (3:7) 4 times, ethyl acetate (100%) 2 times and methanol (100%) 2 times, each made in 200 ml. Then the obtained fractions are accommodated in each container, evaporated to obtain dry fractions. The fractions were then TLC on the activated plate and then eluted with the appropriate eluent and observed under UV light 254 and 366 nm for grouping the fractions based on the similarity of the stains formed. The same spots were identified as having the same chemical components and could be made into a single fraction. All fractions resulting from fractionation using column chromatography were analyzed by TLC using the eluent, which gave the best separation. Prior to separation and purification using Vacuum Liquid Chromatography, the eluent was searched for the appropriate eluent using the eluent TLC technique that was most suitable to be used as a reference in separating using Vacuum Liquid Chromatography. Analysis of the results of the separation was carried out using a UV lamp and the reagent for the staining of cerium sulfate.

**Preparation of experimental animals**

This study was approved by the Animal Research Ethics Committee (AREC), Halu Oleo University Faculty of Medicine (AREC Reg. No: 1827B/UN29.20.1.2/PG/2020) and the experiments were conducted according to the ethical norms and AREC guidelines. The experimental animals used were mice (Swiss Webster strain) aged 2-3 mo with body weights ranging from 20-30 g BW. They were maintained at the Department of Pharmacy, Faculty of Science and Technology, Mandala Waluyo University. The mice were housed at a temperature of 25 °C and fed on rodent pellets and water of libitum. The animals were divided randomly into nine groups, each consisting of 5 animals. Group I as the positive control, Group II as negative control, group III-IX as the fractions testing group. Before treatment, all mice were fasting, then their fasting blood sugar levels were checked. Induction of diabetes in mice was carried out by administering alloxan monohydrate (170 mg/kg BW) intraperitoneally. Blood sugar levels of mice were checked again 48 h after alloxan injection. The parameters for the success of induction are the increase in fasting blood glucose levels that exceed 125 mg/dl [16].

**Experimental design**

Group I: Alloxan treated control (170 mg/kg, ip)+Acarbose 25 mg/kg BW. p. o

Group II: Alloxan treated control (170 mg/kg, ip)+Na-CMC 0.5 %

Group III: Alloxan (170 mg/kg, ip)+Fraction A (100 mg/kg BW)

Group IV: Alloxan (170 mg/kg, ip)+Fraction B (100 mg/kg BW)

Group V: Alloxan (170 mg/kg, ip)+Fraction C (100 mg/kg BW)

Group VI: Alloxan (170 mg/kg, ip)+Fraction D (100 mg/kg BW)

Group VII: Alloxan (170 mg/kg, ip)+Fraction E (100 mg/kg BW)

Group VIII: Alloxan (170 mg/kg, ip)+Fraction F(100 mg/kg BW)

Group IX: Alloxan (170 mg/kg. ip)+Fraction G (100 mg/kg BW)

Blood samples were taken by cutting the tail of the mice and then measuring blood sugar levels using a glucometer for 5 replications on the first, third, seventh and fifteenth days.

**Statistical analysis**

Anti-diabetic test results data are interpreted in the form of averages and percentages. Significant differences between groups were tested using a One-way Analysis of Variance (ANOVA) and followed by post hoc LSD's test. Statistical analysis with p-value=0.05 is considered significant.

**Identification of compounds using liquid chromatography-mass spectrometry (LC-MS/MS)**

The chemical constituents of the fractions were identified using LC-MS/MS Method. LC-MS/MS is the only liquid chromatography technique with a mass spectrometer detector [17]. LC-MS/MS is used to separate several components of a compound or mixture of compounds based on their polarity (the working principle of chromatography), where after the mixture of compounds is separated, then the pure compound will be identified based on its molecular weight. That data obtained is the molecular weight plus some charge and molecular weight solvent [18]. The liquid mobile phase pump flowed through the column to the detector. The sample is injected into the mobile phase stream using the injection method. In the column, there is a separation process for the components of the mixture, which results in differences in the strength of the interaction between the solutions in the stationary phase. The solution with less strong interaction with the stationary phase will leave the column first. On the other hand, when a strong solution interacts with the stationary phase, the solution will leave the column, which is then detected by the detector and recorded in the form of a chromatogram [19]. The LC-MS/MS analysis method was performed using HPLC connected to a Q-TOF spectrometer equipped with an ESI source. Full scan method from m/z to 1200 at 140 C source temperature. Phenomenon HPLC column 5μ C6 (150 x 2 mm i.d.) was used for analysis. The solvent was used methanol with 0.3% formic acid. Solvent delivered at a total flow rate of 0.1 ml/min. Solvent run by isocratic elution. The MS spectrum was obtained in the positive ion mode. Drying gas temperature (N\(_2\)), gas flow rate and nebulization pressure (N\(_2\)) were set at 350 °C, 6 ml/min, and 25 psi, respectively. Furthermore, about 0.5 g sample was diluted with methanol and filtered through a 0.22 µm nylon filter before analysis. Volume 5 µl fraction injected into the analytical column for analysis. Mass spectrometer analysis was performed to determine the mass fragmentation (m/z). The results of the mass spectrometry spectrum were compared with the similarity index (SI) numbers in the mass spectrometry library chromatography library. The similarity index number greater than 92% was considered to have the same fragmentation peak at the peak of liquid chromatography so that the peak is from the same as the compound read on liquid chromatography. The same value of the similarity index of fragmentation at the selected peak fragmentation of the compound with the lowest molecular weight as the analyzed peak fragmentation [20].
RESULTS

In vivo antidiabetic activity test on *L. inermis* leaves fraction with positive control of acarbose and negative control of Na-CMC as well as 7 fractions (A-G) were tested for 15 d of observation on test animals. The results of the in vivo anti-diabetic test on the leaf fraction of *L. inermis* are shown in table 1.

Table 1: Effect of fractions on fasting blood glucose in alloxan-induced diabetic mice

| Group                  | The mean level of blood glucose (mg/dl) | 1st day | 3rd day | 7th day | 15th day |
|------------------------|----------------------------------------|--------|--------|---------|----------|
| Group I (acarbose)     | 65±4.4                                 | 273±3.8| 250±10.0*| 173±25.1*| 91±15.6* | 72±3.0*  |
| Group II (Na CMC)      | 68±3.5                                 | 304±5.1| 267±25.1*| 341±2.9* | 406±13.9*| 418±11.0*|
| Group III (Fraction A) | 62±2.5                                 | 253±4.0| 152±17.0*| 124±25.3*| 103±26.1*| 91±26.1* |
| Group IV (Fraction B)  | 84±2.6                                 | 275±4.3| 158±8.0**| 101±7.0**| 85±10.8**| 68±7.0** |
| Group V (Fraction C)   | 66±3.5                                 | 308±6.2| 181±4.0**| 150±3.0**| 97±10.0**| 82±5.0** |
| Group VI (Fraction D)  | 82±1.7                                 | 384±7.9| 275±6.9**| 256±2.6**| 119±17.4*| 102±6.1**|
| Group VII (Fraction E) | 72±2.7                                 | 233±17.7| 145±20.0**| 125±9.0**| 116±4.6**| 100±12.2**|
| Group VIII (Fraction F)| 68±2.7                                 | 221±7.9| 166±3.5**| 149±18.2*| 131±16.5*| 120±9.1**|
| Group IX (Fraction G)  | 69±2.2                                 | 317±12.2| 234±5.3**| 210±14.7**| 125±4.4**| 103±3.0**|

*Significantly different to acarbose group (p<0.05); significantly different to diabetic group (p<0.05) GLAI: Glucose Levels After Alloxan Induction; FBGL: Fasting Blood Glucose Levels. Data are expressed as means±SD of 5 independent experiments. The results of the anti-diabetic activity test on the fraction of *L. inermis* leaves obtained a significant decrease in blood glucose levels in the fractions B (68±7.0**), C (82±5.0**) and D (100±12.2**). The graph of measuring results of the average blood sugar level in mice can be seen in fig. 1.

Fig. 1: Effect of fractions (A-G) of *L. inermis* leaves in alloxan-induced diabetic mice, *Significantly different to acarbose group (p<0.05); significantly different to diabetic group (p<0.05) GLAI: Glucose Levels After Alloxan Induction; FBGL: Fasting Blood Glucose Levels. Data were expressed as means±SD of 5 independent experiments

Table 2: Identified of compounds contained fractions of *L. inermis* leaves using liquid chromatography-mass spectrometry (LC-MS/MS) method

| Fraction | Compounds                                      | Observed m/z |
|----------|-----------------------------------------------|--------------|
| A        | 12-Hydroxy-methyl abietate                    | 3332396      |
|          | 9,12-Octadecadienoic acid (ZZ)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester | 3953126      |
|          | Candidate Mass C19H28O3                        | 5894806      |
|          | Candidate Mass C19H26O3                        | 6335429      |
|          | Candidate Mass C19H26NO6                       | 4581592      |
| B        | (E)-Hexadecyl-furulate                        | 4193127      |
|          | 9,12-Octadecadienoic acid (ZZ)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester | 3953128      |
|          | Candidate Mass C19H26O3                        | 2822789      |
|          | Candidate Mass C19H26NO7                      | 4603265      |
|          | Candidate Mass C19H26O7                        | 2310499      |
| C        | (E)-Hexadecyl-furulate                        | 4193128      |
|          | 9,12-Octadecadienoic acid (ZZ)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester | 3953130      |
|          | Suaric acid E                                 | 4572926      |
|          | Candidate Mass C19H28O3                        | 6335430      |
|          | Candidate Mass C19H26O3                        | 6575437      |
| D        | Dehydrooramnioglycone                         | 2490757      |
|          | Candidate Mass C19H26O14                      | 4699622      |
|          | Candidate Mass C19H26O12                      | 4619725      |
|          | Candidate Mass C19H26O7                       | 2310495      |
| E        | Bleptolol C                                   | 4631781      |
|          | Moupinamide                                   | 3141382      |
|          | Candidate Mass C19H28O3                       | 2310495      |
|          | Candidate Mass C19H26O3                       | 4791026      |
|          | Candidate Mass C19H26NO14                     | 4699622      |
| F        | Umbelliferone                                 | 1630386      |
|          | Candidate Mass C19H28O3                       | 2310498      |
|          | Candidate Mass C19H26O3                       | 4791032      |
|          | Candidate Mass C19H26NO14                     | 4699624      |
| G        | Umbelliferone                                 | 1630384      |
|          | Valine                                        | 1180858      |
|          | Candidate Mass C19H28O3                       | 3760976      |
|          | Candidate Mass C19H26O7                       | 2661233      |
Fig. 2: Mass spectrums of the compounds from L. inermis leaves fractions (A–G)
These studies were begun with measuring fasting blood glucose levels in all groups of mice. In Table 1, it can be seen the effect of each fraction (A-G) of L. inermis leaves on blood glucose levels after being given alloxan (170 mg/kg BW) intraperitoneally. Group I (acrbose treatment group), Group II (Na-CMC 0.5%), and Group IV-IX (100 mg/kg BW) had a significant increase in blood glucose levels. While the antidiabetic activity of the fractions indicated by a decrease in blood sugar levels in mice on day 15 were 64, 73, 73, 57, 45, and 67%, respectively. The results showed that the average of fasting blood glucose levels in the positive control (acrbose) was 65±4.4 mg/dl, the negative control group (Na CMC 0.5%) was 68±3.5 mg/dl, and the fraction A to fraction G groups at a dose of 100 mg/kg BW were 62±2.5, 84±2.6, 66±3.5, 82±1.7, 72±2.7, 68±2.7, and 69±2.2 mg/dl, respectively. Then the mice were made in a diabetic condition by inducing alloxan monohydrate at a dose of 170 mg/kg BW for 48 h. Blood glucose levels of mice were monitored for 15 days to see the effect of hyperglycemia. The observation showed that the blood glucose levels of the mice with hyperglycemia ranged between 221±7.9-384±7.9 mg/dl. The hyperglycemic mice were then divided at random into 9 groups, consisting of 5 animals in each group. The results showed that reducing blood glucose levels between the acrbose group. Na-CMC group and the test group (A-G Fraction) which has the best effect on reducing blood sugar levels was fraction B, C and D with a decrease value on day 15, namely 68±7.0, 82±5.0, 102±6.1 with a significant value (p<0.05) significantly different from the acrbose group and the Na CMC group. According to [21] compounds from the polyphenol group, flavonoids, saponins/saponides, triterpenes, tannins, alkaloids, steroids, and cardiac glycosides act as antidiabetic with a mechanism of action. Increase glucose absorption, possess insulin-mimetic properties, inhibition of α-amylase and α-glucosidase and interactions with the insulin receptor that leads to the activation of biochemical cascades (PI3K and MAPK). Furthermore, research from [22] phenol and flavonoid compounds acting as antidiabetic by normalizing insulin levels, glucose uptake in peripheral tissues suppresses intestinal glucose uptake, prevents insulin resistance and significantly reverses the effects of fructose and insulin on lipid accumulation and there are alkaloid compounds that have activity anti-diabetic with insulinomimetic properties; inhibit carbohydrate digestion enzymes and prevention of oxidative stress. Based on the data obtained, there are the same compounds in various fractions, the compound 9,12-Octadecadienoic acid (Z,Z)- (2,2-dimethyl-1,3-dioxolan-4-yl) methyl ester is an ester group compound found in fractions A, B, C and while for the compound (E)-4-cinnamoyl-ferulic acid which is a compound with an ester functional group which from the analysis results obtained in fractions B and C. Ester group compounds are also obtained from fraction E, i.e. bletilol C. Esters are compounds derived from carboxylic acid derivatives that undergo oxidation reactions in the hydroxyl group where this carboxylic acid group is in the form of phenylpropanoid which is a cinnamic acid derivative compound. Cinnamic acid is derived from L-Phenylalanine through a deamination reaction. Hydrogenation of cinnamic acid produces P-Coumaric acid, which is an intermediate compound for the formation of phenylpropenoid derivatives, namely p-hydroxy sinapyl alcohol, coniferyl alcohol and sinapyl alcohol. While for compounds derived from fractions F and G there is Umbelliferone compound which is a group of coumarin compounds. Coumarins have similarities to chlorigenic acid and rosmarinic acid can be formed from aromatic amino acids such as L-tyrosine. Modification of L-tyrosine will produce 4-hydroxyphenylpyruvic acid, then through several reaction steps such as reduction and dehydration, rosmarinic acid is produced. While chlorogenic acid can be formed through a substitution reaction between caffeine-CoA and quinic acid. Compounds derived from fraction A were 12-hydroxy-methyl abietate which are derived from the diterpene group of terpenoid compounds composed of CS units (isoprene). Farnesyl pyrophosphate (FPP) cation condensation with isopentenyl pyrophosphate (IPP), followed by proton release to form geranylgeranyl pyrophosphate (GGPP). The next compound from the same compound group is triterpenes in fraction C is siraitic acid E which is composed of 6 units of CS (isoprene). Triterpenoid biosynthesis is not through the addition of IPP to sesquiterpenoid. In the case of squalene, the precursor for triterpenoid and steroid formation is via the fusion of the tails of the two FPP units. While the compounds belonging to the alkaid group were obtained from the E fraction, i.e. moupinamide and the fraction of G in the form of valine, both of these alkaid compounds were derived from the amino acid tyrosine which was oxidized in the aromatic ring to produce dopamine compounds. Furthermore, there are groups of compounds whose names and structures are still unknown from the analysis of the LCMS/MS compounds, including in fraction of A there are compounds with the molecular formula C24H39NO9, C21H31NO4, and C23H33NO8. Meanwhile, in fraction of B, there are also alkaid compounds C19H25NO4 and C20H27NO7. The same compound is present in various fractions among compounds with the molecular formula C19H25NO4 derived from fractions of B, D, E and F. Then the compounds of the alkaid group C19H25NO4, C19H27NO7 and in fraction of D there are compounds of the alkaid group, i.e. C21H31NO11 while in the G fraction there are also alkaid group compounds identified by the molecular formula of the compound C19H25NO4 and C20H27NO7. Moupinamide compound has activity as ethanolic hypoglycemic and anti-hyperglycemic activity [23], Umbelliferone compound according to [24] umbelliferone as a potential antiidiabetic herbal medicine in the management of diabetes. And research from [25] that valine compounds are biomarkers of type 2 diabetes and are associated with the hypoglycemic effect of sitagliptin. CONCLUSION The anti-diabetic activities of fractions (A-G) from the purified extract of L. inermis leaves showed that the decreasing in blood sugar levels at a dose of 100 mg/kg BW occurred on the 15th day of administration with a decreasing in blood sugar level were 64, 73, 73, 57, 45, and 67%, respectively. LC-MS/MS analysis revealed the presence of ester groups, steroid groups, phenylpropanoid groups and alkaloid groups. The presence of these compounds mostly contribute to anti-diabetic activity and based on the results of this study the L. inermis plant on the leaves can be used as a candidate for anti-diabetic drugs. ACKNOWLEDGMENT The authors gratefully acknowledge Universitas Padjadjaran through the Research of Lecturer Competence 2021. FUNDING Nil AUTHORS CONTRIBUTIONS All the authors contributed equally. CONFLICTS OF INTERESTS The authors declare no potential conflicts of interest. REFERENCES 1. Saedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. 9th ed. Diabetes Res Clin Practice. 2019;157:1-10. 2. Musso G, Gambino R, Bo S, Uberti B, Birolí G, Pagano G, Cassidy M. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nonidiabetic subjects. Diabetes Care. 2008;31(3):562-8. doi: 10.2337/dc07-1526; PMID 18056890.
3. Husni E, Suhray N, Atma APT. Characterization of simplicia and determination of total phenolic levels and antioxidant activity test. J Pharm Clin Sci. 2018;5:12-6.

4. Budhadev SG, Budhadev SS. Ayurvedic medicinal plant *Lawsonia inermis* Linn: A complete review. Pharm Sci Monit. 2016;7:240-8.

5. Kamal M, Jawa'd T. Pharmacological activities of *Lawsonia inermis* Linn.: a review. Int J Biol Med Res. 2016;1(2):62-8. doi: 10.7439/ijbmr.v1i2.56.

6. Akram M, Hamid A, Khalil A, Ghafrar A, Tayyaba N, Saeed A, Ali M, Naveed A. Review on medicinal uses, pharmacological, phytochemistry and immunomodulatory activity of plants. Int J Immunopathol Pharmacol. 2014;27(3):313-9. doi: 10.1177/039463201402700301.

7. Inawati I, Syamsuddin S, Winarno H. Effect of inai leaf extract (*Lawsonia inermis* Linn.) against decreased glucose, total cholesterol and blood triglycerides on alloxan-induced mice. J Kimia Indones. 2006;1:71-7.

8. Chaudhary G, Goyal S, Poonia P. *Lawsonia inermis* Linnæus: A phytopharmacological review. Int J Pharm Sci Drug Res. 2010;2:91-8.

9. Li Q, Gao WQ, Zhao YQ. Advances in studies on chemical constituents and biological activities of *Lawsonia inermis* Zhongguo Zhong Yao Za Zhi. 2013;38(6):795-9. PMID 23717954.

10. Li Q, Gao WQ, Zhao YQ. Advances in studies on chemical constituents and biological activities of *Lawsonia inermis* Linn.: A complete review. Pharm Sci Monit. 2017;02(2):79-85. doi: 10.20510/ukjpb/4/i1/90385.

11. Antika MA, Ilyas S, Sari MI. Effect of *Lawsonia inermis* Linn. Ethanol extract on the Superoxyde dismutase activity in hyperglycemic Rattus norvegicus. Indonesian J Med. 2017;02(2):79-85. doi: 10.26911/theijmed.2017.02.02.01.

12. Antika MA, Ilyas S, Sari MI. Effect of *Lawsonia inermis* Linn. Ethanol extract on the Superoxyde dismutase activity in hyperglycemic Rattus norvegicus. Indonesian J Med. 2017;02(2):79-85. doi: 10.26911/theijmed.2017.02.02.01.

13. Zahra F, Harahap U, Haro G. Physicochemical properties, phytochemical screening, and antihyperglycemic activity of inai (*Lawsonia inermis*) leaves active fraction on streptozotocin-induced diabetic mice. Asian J Pharm Clin Res. 2018;11(5):68-71. doi: 10.22159/ajpcr.2018v11i5.23504.

14. Jegodar GA, Maleki M, Motadayen MH, Sirus S. Effect of fenugreek, onion and garlic on blood glucose and histopathology of pancreas of alloxan-induced diabetic rats. Indian J Med Sci. 2008;62(2):64-9. doi: 10.1016/S0199-5359.13935. PMID 15738612.

15. Bowers LD. High-performance liquid chromatography/mass spectrometry: state of the art for the drug analysis laboratory. Clin Chem. 1989;35(7):1282-7. doi: 10.1093/clinchem/35.7.1282.

16. Ardrey RE. Liquid chromatography-mass spectrometry: an introduction. University of Huddersfield, Huddersfield, UK. John Wiley and Sons; 2003.

17. Hanafi H, Irwan C, Rochaeni H, Sulistiyawati L, Roziafanto AN, Supriyono. Phytochemical screening, LC-MS studies and antidiabetic potential of methanol extracts of seed shells of *archidendron bubalimum* (Jack) L. C. nielson (julang Jaling) from Lampung, Indonesia. Pharmacogn J. 2018;10:s7-82.

18. Supandi S, Harahap Y, Harmita H, Andalusia R. Analysis of 6-mercaptopurine and 6-methylmercaptopurine in dried blood spots using liquid chromatography-tandem mass spectrometry and its application in childhood acute lymphoblastic leukemia patient. Asian J Pharm Clin. 2017;10:120-5.

19. Sen P, Sahu K, Prasad P, Chandrakar S, Sahu RK, Roy A. Approach to phytochemistry and mechanism of action of plants having antidiabetic activity. UK J Pharm Biosci. 2008;11(1):81-6. doi: 10.1016/j.jep.2008.05.031, PMID 18588966.

20. Mousinho NM, van Tonder JJ, Steenkamp V. *In vitro* anti-diabetic activity of *sclerocarya birrea* and *Ziziphus mucronata*. Nat Prod Commun. 2013;8(9):1279-84. PMID 24273866.

21. van de Venter M, Roux S, Bungu LC, Louw J, Crouch NR, Grace OM, Maharaj V, Pillay P, Sewmarian P, Bhagwandin N, Folb P. Antidiabetic screening and scoring of 11 plants traditionally used in South Africa. J Ethnopharmacol. 2008;119(1):121-3. doi: 10.1016/j.ejphar.2007.10.002, PMID 17920285.

22. Sen P, Sahu K, Prasad P, Chandrakar S, Sahu RK, Roy A. Approach to phytochemistry and mechanism of action of plants having antidiabetic activity. UK J Pharm Biosci. 2016;4(1):82-120. doi: 10.20510/ukjpb/4/i1/90385.

23. Ramu R, Shirahatti PS, Swamy N, Zameer F, Dhananjaya BL, Nagendra PMN. Assessment of *Musa* sp. var. *Nanjangud rasa bale flower* in hyperglycaemic rodent model. Plos One. 2016;11:1-17.

24. Liao X, Liu B, Qu H, Zhang L, Lu Y, Yu X, Lyu Z, Zheng H. A high level of circulating valine is a biomarker for type 2 diabetes and is associated with the hypoglycemic effect of sitagliptin. Mediators Inflamm. 2019;2019:8247019. doi: 10.1155/2019/8247019. PMID 31827381.